A claim of superiority would have given them better chance at market share given the cost issue. Hopefully the market feels good about chances of success in April and we get some movement before then. The company must feel confident in their data or else they wouldve had more trials-unless cost was an issue?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.